Annolyse
BriefingsCompaniesInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

←Back to companies

EBO · NZX

EBOS Group (EBO)

Healthcare / Healthcare distribution•Covered: HY24 - HY26•5 published briefings

EBOS Group is an NZX-listed healthcare / healthcare distribution company with HY24 - HY26 of published result briefings.

Latest briefing

HY26 · Released 25 February 2026

Cash conversion collapsed to 15.4% as working capital absorbed $348m

Revenue grew 13.0% and FY26 EBITDA guidance was reaffirmed, but operating cash flow fell to $46.6m and the dividend was not covered by free cash flow.

Market data

Latest available
Price
NZD 19.39
Mkt cap
$4b
Yield
6.1%

Quote as of 04-06-2026 4:40pm NZT

Sections⌄
  1. Snapshot
  2. Chat
  3. Longitudinal View
  4. Follow-through
  5. Archive
  6. Related Insights
  1. Snapshot
  2. Chat
  3. Longitudinal View
  4. Follow-through
  5. Archive
  6. Related Insights

Snapshot

Latest metrics

HY26, released 25 February 2026

← Swipe to view more
EBO latest metrics
MetricValueChange
Revenue$6.8b↑ +13.0%
EBITDA$302.7m↑ +9.7%
NPAT$124.8m↑ +12.9%
Operating cash flow$46.6m↓ -75.5%
OCF / EBITDA %15.4%↓ -53.4pp
Net debt$1.1b↑ +5.3%
Net debt / EBITDA3.7x↓ -4.1%
ROE %4.6%↑ +0.1pp
DPS57.0c— Flat
Payout ratio vs NPAT %93.3%↓ -6.9pp

Source: latest published briefing (HY26, released 25 February 2026). Change compares against the prior equivalent period: HY25, released 19 February 2025.

Chat

Ask about EBO

Ask follow-up questions about EBOS Group's latest result and company history.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about EBO

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask company questions.

What changed in the latest result?What is unusual in the historical context?How has cash conversion changed over time?Compare this company with CNU.

Checking account...

Longitudinal view

Performance over time

The latest period is shown first.

← Swipe to view more
EBO metric history
MetricHY266 MONTHS25 February 2026FY2512 MONTHS27 August 2025HY256 MONTHS19 February 2025FY2412 MONTHS21 August 2024HY246 MONTHS21 February 2024Trend
Revenue$6.8b$12.3b$6b$13.2b$6.6b
Chart
Revenue growth %13.0%-7.0%-9.0%7.8%7.1%
Chart
EBITDA$302.7m$555.6m$275.8m$605.6m$303.1m
Chart
EBITDA margin %4.5%4.5%4.6%4.6%4.6%
Chart
PBT$162.7m$302.2m$155.8m$383.1m$192m
Chart
PBT growth %4.4%-21.1%-18.9%2.6%-0.3%
Chart
NPAT$124.8m$215.1m$110.5m$271.5m$136.2m
Chart
NPAT growth %12.9%-20.8%-18.9%7.1%3.0%
Chart
Operating cash flow$46.6m$418.5m$189.8m$348.2m$105.5m
Chart
OCF / EBITDA %15.4%75.3%68.8%57.5%34.8%
Chart
FCF pre-lease-$24m$273m$126m$229.8m$39.1m
Chart
FCF post-lease-$24m$273m$126m$229.8m$39.1m
Chart
DPS57.0c61.5c57.0c61.5c57.0c
Chart
Payout ratio vs NPAT %93.3%108.0%100.2%83.9%80.3%
Chart
Annual payout ratio vs EPS %—108.0%—83.9%—
Chart
ROE %4.6%7.9%4.5%11.2%11.8%
Chart
Net debt$1.1b$918.3m$1.1b$1b$1.1b
Chart
Net debt / EBITDA3.7x1.65x3.86x1.68x3.59x
Chart
Debtor days4541433942
Chart
Inventory days3640383437
Chart
Total assets$7.6b$7.3b$6.8b$6.7b$6.9b
Chart

Reference: annolyse.ai/companies/ebo

Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.

Operating working-capital movement

Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.

↗
Loading chart...

The setup & the reality

FY25 → HY26 Follow-through

The latest result is checked against what the prior briefing said to watch.

Current result now available

HY26 · Released 25 February 2026

Cash conversion collapsed to 15.4% as working capital absorbed $348m

Revenue grew 13.0% and FY26 EBITDA guidance was reaffirmed, but operating cash flow fell to $46.6m and the dividend was not covered by free cash flow.

Read latest briefing→

Historical setup

What FY25 said to watch

From Reported PBT fell 21.1% while cash conversion rose to 75.3%

EBOS confirmed underlying EBITDA of $585m, inside the disclosed range of $575–600m. No forward targets were supplied in the extraction, so this briefing focuses on what the release does and does not support. The HY25 share of FY25 was 48.8% of revenue, 49.6% of EBITDA and 51.4% of NPAT, indicating broadly balanced halves with a marginally softer H2 NPAT.

The release does not provide quantified FY26 guidance. The gap between the 12.0% underlying revenue growth signal and the 15.1% underlying NPAT decline means the forward shape — particularly margin and finance-cost recovery — remains an open question.

Open questions

Open questions from FY25

  • Why did reported revenue fall from $13.2bn to $12.3bn when underlying revenue grew 12.0%, and what residual reported-base headwind carries into FY26?
  • Why did inventory days rise to 40.0 from 33.5, and is the $134.8m inventory build tied to specific contracts or general supply-chain positioning?
  • How sustainable is the 7.5% underlying EBITDA growth once M&A and restructuring add-backs normalise, given underlying NPAT still fell 15.1%?
  • Can the dividend policy continue at 118.5 cents if reported NPAT does not recover toward underlying levels?
  • What drives the path back from FY25 ROE of 7.9% (vs 11.2%) toward prior levels?

This briefing cannot assess whether the disclosed underlying growth is repeatable beyond FY25 or what the FY26 trading shape is expected to look like.

Archive

Briefing archive

Every published Annolyse briefing for this company appears here in reverse chronological order.

HY26 · Released 25 February 2026

Cash conversion collapsed to 15.4% as working capital absorbed $348m

Revenue grew 13.0% and FY26 EBITDA guidance was reaffirmed, but operating cash flow fell to $46.6m and the dividend was not covered by free cash flow.

Read briefing→

FY25 · Released 27 August 2025

Reported PBT fell 21.1% while cash conversion rose to 75.3%

Reported revenue and earnings fell sharply against a non-comparable prior period, but cash generation and leverage strengthened materially.

Read briefing→

HY25 · Released 19 February 2025

NPAT fell 18.9% on a 9.0% revenue decline as dividend held flat

Operating deleverage pushed the NPAT payout ratio to 100.2% while net debt to EBITDA crept up to 3.86x even as cash conversion rebounded.

Read briefing→

FY24 · Released 21 August 2024

NPAT up 7.1% but operating cash flow fell 11% and leverage climbed to 1.68x

Cash conversion slid to 57.5% from 68.8% while the full-year dividend absorbed roughly 99.1% of free cash flow, tightening financial headroom.

Read briefing→

HY24 · Released 21 February 2024

OCF fell 34.5% and leverage rose to 1.8x as inventories built $140m

EBITDA rose 4.8% but operating cash fell 34.5% on a $140.3m inventory build, leaving the lifted 57.0c dividend uncovered by free cash flow.

Read briefing→

Related insights

Compare this company

The latest EBO metrics also appear in these cross-company views.

Insight

Cash conversion quality

This result converted 15.4% of EBITDA to operating cash flow, -53.5pp versus the prior comparable period.

Open insight→

Insight

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 8.5pp, with a distortion flag in the result.

Open insight→

Insight

Leverage and balance-sheet risk

Net debt / EBITDA is 3.70x, -0.16x versus the prior comparable period.

Open insight→

Insight

Dividend coverage and payout pressure

Dividend payout versus NPAT is 93.3%.

Open insight→

Get notified when EBO publishes

Get the next EBOS Group result briefing and five-year history updates by email.